Zi-Yuan Zou
Shanghai Jiao Tong University
EpidemiologyInternal medicineRandomized controlled trialPrevalenceBasal (phylogenetics)Prospective cohort studyHBeAgSteatosisEntecavirNonalcoholic fatty liver diseaseHepatitis BInsulin resistanceFatty liverDiseaseConcomitantSteatohepatitisBody mass indexMetabolic syndromeIncidence (epidemiology)Confidence intervalDiabetes mellitusMedicineGene polymorphismComplicationGastroenterology
3Publications
0Citations
Publications 5
Newest
#1Zi-Yuan Zou (SJTU: Shanghai Jiao Tong University)
#2Jing Zeng (SJTU: Shanghai Jiao Tong University)H-Index: 6
Last. Jian-Gao Fan (SJTU: Shanghai Jiao Tong University)H-Index: 54
view all 9 authors...
BACKGROUND Despite substantial attention paid to the epidemic of nonalcoholic fatty liver disease (NAFLD) in adults, data on the burden and sexual dimorphism of NAFLD in Asian children have not yet been synthesized. METHODS We conducted a literature search of 735 references up to April 2021. Pooled analyses, stratified analyses and meta-regression were all performed. RESULTS Thirty-three study populations were finally included. Nine of them comprising 20 595 children showed an overall NAFLD prev...
Source
Abstract null null Background null Although concomitant nonalcoholic steatohepatitis (NASH) is common in chronic hepatitis B (CHB), the impact of viral factors on NASH and the outcome of CHB patients concomitant with NASH remain unclear. We aimed to investigate the outcomes of NASH in CHB patients receiving antiviral treatment. null null null Methods null In the post-hoc analysis of a multicenter trial, naive CHB patients receiving 72-week entecavir treatment were enrolled. We evaluated the bioc...
Source
Nonalcoholic fatty liver disease, now renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is common in obese patients. Intragastric balloon (IGB), an obesity management tool with low complication risk, might be used in MAFLD treatment but there is still unexplained heterogeneity in results across studies.
Source
Background: Although concomitant non-alcoholic steatohepatitis (NASH) is common in chronic hepatitis B (CHB) patients, the outcome of NASH in CHB patients remains unclear. This study was aimed to evaluate the incidence and resolution rate of NASH in CHB patients during antiviral treatment. Methods: This was a sub-study of a multicenter prospective study on HBV treatment outcomes including patients with or without NASH. The histopathological features of NASH were examined using paired liver biops...
Source
#1Zi-Yuan Zou (SJTU: Shanghai Jiao Tong University)
#2Vincent Wai-Sun Wong (CUHK: The Chinese University of Hong Kong)H-Index: 105
Last. Jian-Gao Fan (SJTU: Shanghai Jiao Tong University)H-Index: 54
view all 3 authors...
Background & Aims: As a subpopulation of nonalcoholic fatty liver disease (NAFLD), non-obese NAFLD may also have increased risk of adverse hepatic and metabolic outcomes. We estimated the prevalence of non-obese NAFLD and described its clinical characteristics. Methods: We performed a systematic search of 1,891 citations up to April 2019. Results: Of the 40 studies included, 29 cross-sectional/longitudinal studies comprising 157,904 non-obese subjects reported a pooled NAFLD prevalence of 15.8% ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.